Background: Recently, Cp and Temozolamide (Tz) treatment has been investigated in NET in several studies, with heterogeneous populations and outcomes. Cp plus Tz reported a median PFS of about 13 months and it seems more efficient in pancreatic NET. Results from phase II and non-randomized trials with fluoropyrimidine in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with A.
Contact A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack